Evidence map›Paper›PMID 41301827›Full record

ArticleBiomedicines2025

Real-World Data of Light Chain (AL) Amyloidosis: Prognostic Indices and Treatment Patterns.

Marko Mitrovic, Aleksandra Sretenovic, Natalija Kecman, Nikola Vukosavljevic, Maja Perunicic Jovanovic, Dragana Sobic Saranovic, Ruzica Maksimovic, Zoran Bukumiric, Danijela Lekovic, Arsen Ristic and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marko MitrovicClinic of Hematology, Department for Multiple Myeloma, University Clinical Center of Serbia, 11 000 Belgrade, Serbia.
Aleksandra SretenovicClinic of Hematology, Department for Multiple Myeloma, University Clinical Center of Serbia, 11 000 Belgrade, Serbia.
Natalija KecmanClinic of Hematology, Department for Multiple Myeloma, University Clinical Center of Serbia, 11 000 Belgrade, Serbia.
Nikola VukosavljevicDepartment for Hemato-Oncology, University Medical Center "Zvezdara", 11 000 Belgrade, Serbia.
Maja Perunicic JovanovicClinic of Hematology, Department for Multiple Myeloma, University Clinical Center of Serbia, 11 000 Belgrade, Serbia.
Dragana Sobic SaranovicMedical Faculty, University of Belgrade, 11 000 Belgrade, Serbia.
Ruzica MaksimovicMedical Faculty, University of Belgrade, 11 000 Belgrade, Serbia.
Zoran BukumiricInstitute of Statistics and Bioinformatics, Medical Faculty, University of Belgrade, 11 000 Belgrade, Serbia.ORCID 0000-0002-7609-4504
Danijela LekovicMedical Faculty, University of Belgrade, 11 000 Belgrade, Serbia.ORCID 0000-0002-6194-8298
Arsen RisticMedical Faculty, University of Belgrade, 11 000 Belgrade, Serbia.
Milena Todorovic BalintMedical Faculty, University of Belgrade, 11 000 Belgrade, Serbia.
Jelena BilaClinic of Hematology, Department for Multiple Myeloma, University Clinical Center of Serbia, 11 000 Belgrade, Serbia.ORCID 0000-0003-2025-9653

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AL amyloidosisprognosisreal-world datatreatment

Identifiers

PMID41301827
PMCPMC12650509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.